Global Variations in Biologics Access and Rheumatoid Arthritis Treatment Costs

Value in Health - United Kingdom
doi 10.1016/j.jval.2013.08.1470
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

The Cost-Effectiveness of Biologics for the Treatment of Rheumatoid Arthritis: A Systematic Review

PLoS ONE
Multidisciplinary
2015English

Treatment Patterns, Direct Cost of Biologics, and Direct Medical Costs for Rheumatoid Arthritis Patients: A Real-World Analysis of Nationwide Japanese Claims Data

Clinical Therapeutics
Pharmacology
2016English

Impact of Plan-Level Access Restrictions on Effectiveness of Biologics Among Patients With Rheumatoid or Psoriatic Arthritis

PharmacoEconomics - Open
Health PolicyPharmacology
2019English

Biologic Refractory Disease in Rheumatoid Arthritis: Results From the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis

Annals of the Rheumatic Diseases
ImmunologyMolecular BiologyBiochemistryRheumatologyAllergyGenetics
2018English

AB0384 Clinical and Radiological Evolution in Rheumatoid Arthritis (RA) Patients After Deintesificate Biologics

2017English

AB0313 Cardiovascular Risk, Biologics and Anti-Cyclic Citrullinated Peptide Positivity in Rheumatoid Arthritis

2017English

Treatment of Rheumatoid Arthritis

Rheumatology
RheumatologyPharmacology
1997English

Treatment of Rheumatoid Arthritis

1981English

Treatment of Rheumatoid Arthritis

BMJ
1949English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy